Melanocortin-1 receptor (MC1R) plays a key role in skin pigmentation, and its variants are linked with a higher melanoma risk. The influence of MC1R variants on the outcomes of patients with metastatic melanoma (MM) treated with BRAF inhibitors (BRAFi) is unknown. We studied the MC1R status in a cohort of 53 consecutive BRAF-mutated patients with MM treated with BRAFi. We also evaluated the effect of vemurafenib in four V600BRAF melanoma cell lines with/without MC1R variants. We found a significant correlation between the presence of MC1R variants and worse outcomes in terms of both overall response rate (ORR; 59% versus 95%, P = 0.011 univariate, P = 0.028 multivariate analysis) and progression-free survival (PFS) shorter than 6 months (72% versus 33%, P = 0.012 univariate, P = 0.027 multivariate analysis). No difference in overall survival (OS) was reported, probably due to subsequent treatments. Data in vitro showed a significant different phosphorylation of Erk1/2 and p38 MAPK during treatment, associated with a greater increase in vemurafenib IC50 in MC1R variant cell lines.

Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors / Guida, M.; Strippoli, S.; Ferretta, A.; Bartolomeo, N.; Porcelli, L.; Maida, I.; Azzariti, A.; Tommasi, S.; Grieco, C.; Guida, S.; Albano, A.; Lorusso, V.; Guida, G.. - In: PIGMENT CELL & MELANOMA RESEARCH. - ISSN 1755-1471. - 29:6(2016), pp. 679-687. [10.1111/pcmr.12516]

Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors

Guida S.;
2016

Abstract

Melanocortin-1 receptor (MC1R) plays a key role in skin pigmentation, and its variants are linked with a higher melanoma risk. The influence of MC1R variants on the outcomes of patients with metastatic melanoma (MM) treated with BRAF inhibitors (BRAFi) is unknown. We studied the MC1R status in a cohort of 53 consecutive BRAF-mutated patients with MM treated with BRAFi. We also evaluated the effect of vemurafenib in four V600BRAF melanoma cell lines with/without MC1R variants. We found a significant correlation between the presence of MC1R variants and worse outcomes in terms of both overall response rate (ORR; 59% versus 95%, P = 0.011 univariate, P = 0.028 multivariate analysis) and progression-free survival (PFS) shorter than 6 months (72% versus 33%, P = 0.012 univariate, P = 0.027 multivariate analysis). No difference in overall survival (OS) was reported, probably due to subsequent treatments. Data in vitro showed a significant different phosphorylation of Erk1/2 and p38 MAPK during treatment, associated with a greater increase in vemurafenib IC50 in MC1R variant cell lines.
2016
29
6
679
687
Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors / Guida, M.; Strippoli, S.; Ferretta, A.; Bartolomeo, N.; Porcelli, L.; Maida, I.; Azzariti, A.; Tommasi, S.; Grieco, C.; Guida, S.; Albano, A.; Lorusso, V.; Guida, G.. - In: PIGMENT CELL & MELANOMA RESEARCH. - ISSN 1755-1471. - 29:6(2016), pp. 679-687. [10.1111/pcmr.12516]
Guida, M.; Strippoli, S.; Ferretta, A.; Bartolomeo, N.; Porcelli, L.; Maida, I.; Azzariti, A.; Tommasi, S.; Grieco, C.; Guida, S.; Albano, A.; Lorusso, V.; Guida, G.
File in questo prodotto:
File Dimensione Formato  
pcmr.12516.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 569.79 kB
Formato Adobe PDF
569.79 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1204477
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 7
social impact